NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS
REQUEST FOR COVERAGE OF RESTRICTED PROTON PUMP INHIBITORS (PPIs)

PATIENT INFORMATION

PATIENT'S SURNAME	PATIENT'S GIVEN NAME	HEALTH CARD NUMBER	DATE OF BIRTH

DRUG & DOSAGE REQUESTED

Above standard dose omeprazole, pantoprazole magnesium or rabeprazole

Omeprazole, pantoprazole magnesium and rabeprazole are regular benefits at the standard daily doses (maximum of 400 tablets/capsules per year). No form required.

☐ Omeprazole____mg_____ ☐ Pantoprazole ____mg_____ magnesium ☐ Rabeprazole____mg_____

Coverage duration: 8 week trial, followed by up to one year of coverage

Standard dose of restricted PPIs

☐ Lansoprazole_____mg_____ ☐ Pantoprazole sodium_____mg_____

Coverage duration: yearly coverage

PPI MEDICATION HISTORY

Agents Tried:	Dose, length of therapy & outcome: (i.e. inadequate symptom control, wearing off, etc.)
☐ Omeprazole	_____
☐ Rabeprazole	_____
☐ Pantoprazole magnesium	_____
☐ Pantoprazole sodium	_____
☐ Lansoprazole	_____
☐ Other_____	

DIAGNOSIS

☐ Symptomatic GERD ☐ Peptic Ulcer Disease (gastric, duodenal ulcers)

☐ Erosive Esophagitis, Barrett's Esophagitis ☐ Other_____

For double dose requests, please check that the following points have been considered:
(Strategies proposed in consultation with Gastroenterology Capital Health for optimal response to PPIs)

☐ PPI is being taken thirty minutes prior to breakfast, on an empty stomach (before ANY food or drink).

☐ No food or drink after the main evening meal (at least 2 hours before going to bed).

☐ Other causes of gastric upset (NSAIDS, bisphosphonates, etc.) have been considered.

Please note that recent evidence[1, 2] has raised concerns about the extensive use of double dose PPIs. The concerns include:

- **The lack of a clinically significant benefit double dose has over standard dose for many conditions.**
- **Potential adverse effects with PPI use (e.g., observational data suggesting increased risk for *Clostridium difficile* infections, pneumonia, hip fractures, and gastric polyps) which have occurred with both standard and higher doses.**
- **Increased cost.**

1. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) PPI therapy 2007 http://www.cadth.ca/index.php/en/compus/ppis
2. Dalhousie Academic Detailing PPIs: Burning Questions 2008 http://cme.medicine.dal.ca/ad_resources.htm#ppi

PHYSICIAN'S NAME & ADDRESS:

CPSNS #: _____

_____ **PHYSICIAN'S SIGNATURE**

_____ **DATE**

Please Return Form To: Nova Scotia Pharmacare Department, P.O. Box 500, Halifax, NS B3J 2S1 FAX:(902)468-9402